Dialyzers, Dialysates, and Water Treatment

  • Nuhad Ismail
  • Bryan Becker
  • Raymond M. Hakim


Hemodialysis is a complex process performed with apparent simplicity. The major extracorporeal components of this therapy are dialyzers, dialysate, and water treatment systems. In this chapter, we will present a brief synopsis of dialyzers and their operative features and will discuss dialysate composition and water treatment systems.


Reverse Osmosis Granular Activate Carbon Water Treatment System Reverse Osmosis Membrane Bicarbonate Dialysate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ono T, Kataoka H, Kunimoto T: Quantitative analysis on the removal of b2-microglobulin from chronic dialysis patients. Blood Purif 4: 212–214, 1985.Google Scholar
  2. 2.
    Kuhle C, Fricke H, Weld E, Schifft H: High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol 16: 484–488, 1996.CrossRefGoogle Scholar
  3. 3.
    Mujais SK, and Ivanovich P: Membranes for extracorporeal therapy. In: Replacement of Renal Function by Dialysis. J Matier, editor, 3rd edition 1989.Google Scholar
  4. 4.
    Gohl H, Konstantin P: Membrane and filters for hemofiltration. In: LW Henderson, EA Quellhorst, CA Baldamus, MJ Lysaght, eds, Hemofiltration. Springer-Verlag, Berlin, p 41, 1986.Google Scholar
  5. 5.
    Leypoldt JK, Frigon RP, Henderson LW: Macromolecular charge affects hemofilter solute sieving. Trans Am Soc Artif Intern Organs 32: 384–387, 1986.Google Scholar
  6. 6.
    Konstantin P, Bailey RM: Polycarbonate-polyether (PC-PE) flat sheet membrane: manufacture, structure and performance. Blood Purif 4: 6–12, 1985.CrossRefGoogle Scholar
  7. 7.
    Gohl H, Raff M, Harttig D, Deppisch R: PC-PE hollow-fiber membrane structure, performance characteristics, and manufacturing. Blood Purif 4: 23–31, 1985.Google Scholar
  8. 8.
    Akizawa T, Kitaoka T, Koshikawa S, Watanabe T, Imamura K, Tsurumi T, Suma Y, Eiga S: Development of a regenerated cellulose non-complement activating membrane for hemodialysis. Trans Am Soc Artif Intern Organs 32: 76–84, 1986.Google Scholar
  9. 9.
    Hildebrand U, Quellhorst E: Influence of various membranes on the coagulation system during dialysis. Contrib Nephrol 46: 92–101, 1985.PubMedGoogle Scholar
  10. 10.
    Van Stone JC: Hemodialysis apparatus. In: JT Daugirdas, TS Ing, Handbook of Dialysis, 2nd ed, Little, Brown, Boston, p 29, 1988.Google Scholar
  11. 11.
    Kaufman AM, Frinak S, Godmere RO, Levin NW: Clinical experience with heat sterilization for reprocessing dialyzers. ASAIO J 38: M338 - M340, 1992.PubMedCrossRefGoogle Scholar
  12. 12.
    Sigdell Jan Erik: Operating characteristics of hollow-fiber dialyzers. In: AR Nissenson, RN Fine, DE Gentile, eds, Clinical Dialysis, 2nd ed. Appleton and Lange, San Mateo, CA, pp 106–107, 1990.Google Scholar
  13. 13.
    Hakim RM: Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 44: 484–494, 1993.PubMedCrossRefGoogle Scholar
  14. 14.
    Arnout MA, Hakim RM, Todd RF, Dana N, Colten HR: Increased expression of an adhesion promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 312: 457–462, 1985.CrossRefGoogle Scholar
  15. 15.
    Dinarello CA: Cytokines and biocompatibility. Blood Purif 8: 208–213, 1990.PubMedCrossRefGoogle Scholar
  16. 16.
    Strasser T, Schiffi H: Generation of leukotriene B4 by hemodialyzer membranes: a novel index of biocompatibility. Klin Wochenschr 69: 808–812, 1991.PubMedCrossRefGoogle Scholar
  17. 17.
    Craddock PR, Fehr J, Delmasso AP, Brigham KL, Jacob HS: Hemodialysis leukopenia: pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 59: 878–888, 1977.CrossRefGoogle Scholar
  18. 18.
    Rault RB, Silver MR: Severe reactions during hemodialysis. Am J Kidney Dis 5: 128–135, 1985.PubMedGoogle Scholar
  19. 19.
    Walker JF, Lindsay RM, Peters SD, Sibbalb WJ, Linton AL: A sheep model to examine the cardiopulmonary maniestations of blood dialyzer interactions. Am Soc Artif Intern Organs 6: 123–130, 1983.Google Scholar
  20. 20.
    Hakim RM, Breillatt J, Lazarus JM, Port FK: Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med 311: 878–882, 1984.PubMedCrossRefGoogle Scholar
  21. 21.
    Daugirdas JT, Ing TS: First use reactions during hemodialysis: a definition of subtypes. Kidney Int 33 (Suppl 24): 537 - S43, 1988.Google Scholar
  22. 22.
    Pegues DA, Beck-Sague CM, Woollen SW, Greenspan B, Burns SM, Bland LA, Arduino MJ, Favero MS, Mackow RC, Jarvis WR: Anaphylactoid reactions associated with reuse of hollow-fiber hemodialyzers and ACE inhibitors. Kidney Int 42: 1232–1237, 1992.PubMedCrossRefGoogle Scholar
  23. 23.
    Hakim RM, Fearon DT, Lazarus JM: Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int 26: 194–210, 1984.PubMedCrossRefGoogle Scholar
  24. 24.
    Himmelfarb J, Lazarus M, Hakim R: Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 3: 271–276, 1991.Google Scholar
  25. 25.
    Arora N, Lambrou FH, Stewart MW, Vidrine-Parks L, Sandroni S: Sudden blindness associated with central nervous symptoms in a hemodialysis patient. Nephron 59: 490492, 1991.Google Scholar
  26. 26.
    Davenport A, Williams Ai: The effect of dialyzer reuse on peak expiratory flow rate. Respir Med 84: 17–21, 1990.PubMedCrossRefGoogle Scholar
  27. 27.
    Stone WJ, Hakim RM: b2m amyloidosis in long-term hemodialysis patients. Am J Nephrol 9: 177–183, 1989.PubMedCrossRefGoogle Scholar
  28. 28.
    Brunner FP, Brynger H, Ehrich JHH: Case control study on dialysis arthropathy: the influence of two different dialysis membranes:data from the EDTA registry. Nephrol Dial Transplant 5: 432–436, 1990.PubMedCrossRefGoogle Scholar
  29. 29.
    van Ypersele de Strihou C, Jadoul M, Malghem J, Maldague B, Jamart J: Effect of dialysis membrane and patient’s age on signs of dialysis-related amyloidosis. Kidney Int 39: 1012 1019, 1991.Google Scholar
  30. 30.
    Chanard J, Bindi P, Lavand S: Carpal tunnel syndrome and type of dialysis membrane. Br J Med 298: 867–868, 1989.CrossRefGoogle Scholar
  31. 31.
    Jahn B, Betz M, Deppisch R, Janssen O, Hansch GM, Ritz E: Stimulation of b2m synthesis in lymphocytes after exposure to cuprophane dialyzer membranes. Kidney Int 405: 285–290, 1991.CrossRefGoogle Scholar
  32. 32.
    Lemke RP, Hample H, Lobech H: Lysine-specific cleavage of b2-m in amyloid deposits associated with hemodialysis. Kidney Int 36: 675–681, 1989.CrossRefGoogle Scholar
  33. 33.
    DiRaimondo CR, Pollak VE: b2m kinetics in maintenance hemodialysis: a comparison of conventional and high-flux dialyzers and the effects of dialyzer reuse. Am J Kidney Dis 5: 390–395, 1989.Google Scholar
  34. 34.
    Conger JD: Does hemodialysis delay recovery from acute renal failure? Semin Dial 3: 146–148, 1990.CrossRefGoogle Scholar
  35. 35.
    Solez K, Morel-Moroger L, Sraer JD: The morphology of “acute tubular necrosis in man.” Medicine (Baltimore) 58: 362–376, 1979.Google Scholar
  36. 36.
    Badr KF, Schreiner GF, Wasserman M, Ichikawa I: Preservation of the glomerular capillary ultrafiltration coefficient during rat nephrotoxic serum nephritis by a specific leukotriene D4 receptor antagonist. J Clin Invest 81: 1702–1709, 1988.PubMedCrossRefGoogle Scholar
  37. 37.
    Linas SL, Whittenburg D, Parsons P, Repine JE: Mild renal ischemia activates primed neutrophils to cause acute renal failure. Kidney Int 42: 610–616, 1992.PubMedCrossRefGoogle Scholar
  38. 38.
    Schulman G, Fogo A, Gung A, Badr K, Hakim R: Complement activation retards resolution of acute ischemic renal failure in the rat. Kidney Int 40: 1069–1074, 1991.PubMedCrossRefGoogle Scholar
  39. 39.
    Hornberger JC, Chernew M, Petersen J, Garber AM: A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 3: 1227–1237, 1993.Google Scholar
  40. 40.
    Zaoui P, Hakim RM: Natural killer cell function in hemodialysis patients: effect of the dialysis membrane. Kidney Int 43: 1298–1305, 1993.PubMedCrossRefGoogle Scholar
  41. 41.
    Degiannis D, Czarnecki M, Donati D: Normal T lymphocyte function in patients with end stage renal disease hemodialyzed with polysulfone membranes. Am J Nephrol 10: 276–282, 1990.PubMedCrossRefGoogle Scholar
  42. 42.
    Donati D, Degiannis D, Coates N, Raskova J, Raska K Jr: Mixed lymphocyte reaction-induced release of soluble IL-2 receptor. Transplantation 51: 518–523, 1991.CrossRefGoogle Scholar
  43. 43.
    Guiterrez A, Alvestrand A, Wahren J, Bergstrom J: Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 38: 487–494, 1990.CrossRefGoogle Scholar
  44. 44.
    Guiterrez A, Alvestrand A, Bergstrom J: Membrane selection and muscle protein catabolism. Kidney Int 42: S86 — S90, 1992.Google Scholar
  45. 45.
    Lindsay RM, Spanner EA, Heidenheim P, Kortas C, Blake PG: PCR, Kt/V and membrane. Kidney Int 43 (Suppl 41): 5268–5273, 1993.Google Scholar
  46. 46.
    Chanard J, Brunois JP, Melin JP, Lavaud S, Toupance O: Long term results of dialysis therapy with a highly permeable membrane. Artif Organs 6: 262–266, 1982.Google Scholar
  47. 47.
    Van Stone JC: Hemodialysis apparatus. In: JT Daugirdas, TS Ing, ed, Handbook of Dialysis, 3rd ed. Little, Brown, Boston, p 29, 1993.Google Scholar
  48. 48.
    Mendelssohn S, Swartz CD, Yudis M, Onesti G, Ramirez O, Brest AN: High glucose concentration dialysate in chronic hemodialysis. Trans ASAIO 13: 249–253, 1967.Google Scholar
  49. 49.
    Rosborough DC, Van Stone JC: Dialysate glucose. Semin Dial 6: 260–263, 1993.CrossRefGoogle Scholar
  50. 50.
    Ward RA, Wathen RL, Williams TE, Harding GB: Hemodialysate composition and intradialytic metabolic, acid—base, and potassium changes. Kidney Int 32: 129–35, 1987.PubMedCrossRefGoogle Scholar
  51. 51.
    Wathen RA, Keshairah P, Hommeyer P, Cadwell K, Comty CM: The metabolic effects of hemodialysis with and without glucose in the dialysate. Am J Clin Nutr 31: 1870–1875, 1978.PubMedGoogle Scholar
  52. 52.
    Grajower MM, Walter L, Albin J: Hypoglycemia in chronic hemodialysis patients: association with progranolol use. Nephron 26: 126–129, 1980.PubMedCrossRefGoogle Scholar
  53. 53.
    Uraemic hypoglycaemia. Lancet 1: 660–661, 1986.Google Scholar
  54. 54.
    Ganda OP, Aoki TT, Soeldner JS, Morrison RS, Cahill GF Jr: Hormone-fuel concentrations in anephric subjects: effects of hemodialysis (with special reference to amino acids). J Clin Invest 57: 1403–1411, 1976.Google Scholar
  55. 55.
    Koppel JD, Swendseid ME, Shinaberger JH, Umezawa CY: The free and bound amino acids removed by hemodialysis. Trans ASAIO 19: 309–303, 1973.CrossRefGoogle Scholar
  56. 56.
    Ward RA, Shirlow MJ, Hayes JM, Chapman GV, Farrel PC: Protein catabolism during hemodialysis. Am J Clin Nutr 32: 2443–2449, 1979.PubMedGoogle Scholar
  57. 57.
    Hubner W, Sieberth HG, Diemer A, Finke K, Prange E: Effects of regular hemodialysis with glucose and glucose free dialysate on hyperlipemia. Proc EDTA 8: 174–181, 1971.Google Scholar
  58. 58.
    Ramirez G, Butcher DE, Morrison AO: Glucose concentration in the dialysate and lipid abnormalities in chronic hemodialysis patients. Int J Artif Organs 10: 31–36, 1987.PubMedGoogle Scholar
  59. 59.
    Ramirez G, Bercaw BL, Butcher DE, Mathis HL, Brueggemeyer C, Newton JL: The role of glucose in hemodialysis: the effect of glucose free dialysate. Am J Kidney Dis 7: 413–420, 1986.PubMedGoogle Scholar
  60. 60.
    Daugirdas JT: Dialysis hypotension: a hemodynamic analysis. Kidney Int 39: 233–246, 1991.PubMedCrossRefGoogle Scholar
  61. 61.
    de Vries PM: Plasma volume changes during hemodialysis. Semin Dial 5: 42–47, 1992.CrossRefGoogle Scholar
  62. 62.
    Sherman RA: The pathophysiologic basis for hemodialysisrelated hypotension. Semin Dial 1: 136–142, 1988.CrossRefGoogle Scholar
  63. 63.
    Palmer BF: The effect of dialysate composition on systemic hemodynamics. Semin Dialy 5: 54–60, 1992.CrossRefGoogle Scholar
  64. 64.
    Kinet JP, Soyeur D, Ballard N, Saint-Remy M, Collilgnon P, Godon J-P: Hemodynamic study of hypotension during hemodialysis. Kidney Int 21: 868–876, 1982.PubMedCrossRefGoogle Scholar
  65. 65.
    Rouby JJ, Rottembourg J, Durande JP, Basset JY, Doogoulet P, Glaser P, Legrain M: Hemodynamic changes induced by regular hemodialysis and sequential ultrafiltration hemodialysis: a comparative study. Kidney Int 17: 808810, 1980.Google Scholar
  66. 66.
    Wehle B, Asaba H, Castenfors J, Furst P, Gunnaroson B, Shaldon S, Bergstrom J: Hemodynamic changes during sequential ultrafiltration and dialysis. Kidney Int 15: 411–418, 1979.PubMedCrossRefGoogle Scholar
  67. 67.
    Baldamus CA, Ernst W, Frei U, Koch KM: Sympathetic and hemodynamic response to volume removal during different forms of renal replacement therapy. Nephron 31: 324–332, 1982.PubMedCrossRefGoogle Scholar
  68. 68.
    Petitclerc T, Drueke T, Man N, Funck-Brentano JL: Cardiovascular stability on hemodialysis. Adv Nephrol 16: 351–370, 1987.Google Scholar
  69. 69.
    Raja R, Henriquez M, Kramer M, Rosenbaum JL: Intradialytic hypotension—role of osmolar changes and acetate influx. Artif Organs 9: 17–21, 1985.CrossRefGoogle Scholar
  70. 70.
    Henrich WL, Woodard TD, Blachley JD, Gomez-Sanches C, Pettinger W, Cronin RE: Role of osmolality in blood pressure stability after dialysis and ultrafiltration. Kidney Int 18: 480–488, 1980.PubMedCrossRefGoogle Scholar
  71. 71.
    Dumler F, Grondin G, Levin NW: Sequential high/low sodium hemodialysis: an alternative to ultrafiltration. Trans ASAIO 25: 351–353, 1979.CrossRefGoogle Scholar
  72. 72.
    Daugirdas JT, Al-Kudsi RR, Ing TS, Norusis MJ: A double-blind evaluation of sodium gradient hemodialysis. Am J Nephrol 5: 163–168, 1985.PubMedCrossRefGoogle Scholar
  73. 73.
    Raja R, Kramer M, Barber K, Chen S: Sequential changes in dialysate sodium (DNa) during hemodialysis. Trans ASAIO 24: 649–651, 1983.Google Scholar
  74. 74.
    Bedichek E, Kirschbaum B, Sica D: Comparison of the hemodynamic and hormonal effects of hemodialysis using programmable vs constant sodium dialysate (abstract). J Am Soc Nephrol 3: 354, 1992.Google Scholar
  75. 75.
    Heineken FS, Evans MC, Keen ML: Intercompartmental fluid shifts in hemodialysis patients. Biotechnol Prog 3: 69, 1987.CrossRefGoogle Scholar
  76. 76.
    Star RA, Hootkins R, Thompson JR, Pool T, Toto RD: Variability and stability of two pool urea mass transfer coefficient (abstract). J Am Soc Nephrol 3: 395, 1992.Google Scholar
  77. 77.
    Tokars JI, Alter MJ, Faverso MS: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention: National surveillance of dialysis-associated diseases in the United States, 1992. USDHHS, 1992.Google Scholar
  78. 78.
    Leunissen KML, Hoorntje SJ, Fiers HA, Dekkers WT, Mulder AW: Acetate versus bicarbonate hemodialysis in critically ill patients. Nephron 42: 146–151, 1986.PubMedCrossRefGoogle Scholar
  79. 79.
    Graefe U, Milutenovich J, Follette WC, Vizzo JE, Babb AL, Scribner BH: Less dialysis induced morbidity and vascular instability with bicarbonate in dialysate. Ann Intern Med 88: 332–336, 1978.PubMedCrossRefGoogle Scholar
  80. 80.
    Vincent JL, Vanherweghem JL, Degante JP, Berre J, Dufaye P, Kahn RJ: Acetate induced myocardial depression during hemodialysis for acute renal failure. Kidney Int 22: 653–657, 1982.PubMedCrossRefGoogle Scholar
  81. 81.
    Novello A, Kelsch RC, Easterling RE: Acetate intolerance during hemodialysis. Clin Nephrol 5: 29–32, 1976.PubMedGoogle Scholar
  82. 82.
    Hakim RM, Ponzer M-A, Tilton D, Lazarus JM, Gottlieb MN: Effects of acetate and bicarbonate dialysate in stable chronic dialysis patients. Kidney Int 28: 535–540, 1985.PubMedCrossRefGoogle Scholar
  83. 83.
    Tolchin N, Roberts JL, Hayashi J, Lewis EJ: Metabolic consequences of high mass-transfer hemodialysis. Kidney Int 11: 306, 1977.CrossRefGoogle Scholar
  84. 84.
    Henrich WL: Hemodynamic instability during hemodialysis. Kidney Int 30: 605–612, 1986.PubMedCrossRefGoogle Scholar
  85. 85.
    Lonnemann G, Bingel M, Koch KM, Shaldon S, Dinarello CA: Plasma interleukin-1 activity in humans undergoing hemodialysis with regenerated cellulosic membranes. Lymphokine Res 6: 63–70, 1987.PubMedGoogle Scholar
  86. 86.
    Garella S, Chang BS: Hemodialysis-associated hypoxemia. Am J Nephrol 4: 273–279, 1984.PubMedCrossRefGoogle Scholar
  87. 87.
    Ross EA, Nissenson AR: Dialysis-associated hypoxemia: insights into pathophysiology and prevention. Semin Dial 1: 3339, 1988.Google Scholar
  88. 88.
    Wolff J, Pendersen T, Rossen M, Cleeman-Rasmussen K: Effects of acetate and bicarbonate dialysis on cardiac performance, transmural myocardial perfusion and acid–base balance. Int J Artif Organs 9: 105–110, 1986.PubMedGoogle Scholar
  89. 89.
    Vaziri ND, Wilson A, Mukai D, Daruish R, Rutz A, Hyatt J, Moreno C: Dialysis hypoxemia—role for dialyzer membrane and dialysate delivery system. Am J Med 77: 828–833, 1984.PubMedCrossRefGoogle Scholar
  90. 90.
    Henrich WL, Woodard TD, Meyer BD, Chappell TR, Rubin L: High sodium bicarbonate and acetate hemodialysis: double blind crossover comparison of hemodynamic and ventilatory effects. Kidney Int 24: 240–245, 1983.PubMedCrossRefGoogle Scholar
  91. 91.
    Velez RL, Woodard TD, Henrich WL: Acetate and bicarbonate hemodialysis in patients with and without autonomic dysfunction. Kidney Int 26: 59–65, 1984.PubMedCrossRefGoogle Scholar
  92. 92.
    Mehta BR, Fischer D, Ahmad M, Dubose TD: Effects of acetate and bicarbonate hemodialysis on cardiac function in chronic dialysis patients. Kidney Int 24: 782–787, 1983.PubMedCrossRefGoogle Scholar
  93. 93.
    Vinay P, Prud’homme M, Vinet B, Cournoyer G, Degouet P, Ceville M, Gougoux A, St-Louis G, Lapierre L, Piette Y: Acetate metabolism and bicarbonate generation during hemodialysis: 10 years of observation. Kidney Int 31: 1194 1204, 1987.Google Scholar
  94. 94.
    Feinfeld DA, Sherwood LM: Parathyroid hormone and 1,225(OH)3D3 in chronic renal failure. Kidney Int 33: 1049 1058, 1988.Google Scholar
  95. 95.
    Felsenfeld AJ, Rodriguez M, Dunlay R, Llach F: A comparison of parathyroid gland function in hemodialysis patients with different forms of renal osteodystrophy. Nephrol Dial Transplant 6: 244–251, 1991.PubMedCrossRefGoogle Scholar
  96. 96.
    Wing AJ: Optimum calcium concentration of dialysis fluid for maintenance haemodialysis. Br Med J 4: 145, 1968.PubMedCrossRefGoogle Scholar
  97. 97.
    Johnson WJ, Goldsmith RS, Beabout JW. Prevention and reversal of secondary hyperparathyroidism in patients maintained by hemodialysis. Am J Med 56: 827–830, 1974.PubMedCrossRefGoogle Scholar
  98. 98.
    Maynard JC, Cruz C, Kleerekoper M, Levin NW: Blood pressure response to changes in serum ionized calcium during hemodialysis. Ann Intern Med 104: 358–361, 1986.PubMedCrossRefGoogle Scholar
  99. 99.
    Sherman RA, Bialy GB, Gazinski B, Bernholc AS, Eisinger RP: The effect of dialysate calcium levels on blood pressure during hemodialysis. Am J Kidney Dis 8: 244–247, 1986.PubMedGoogle Scholar
  100. 100.
    Feltner SK, Lang RM, Neumann A, Spencer KT, Bushinsky DA, Borow KM: Physiological mechanisms for calcium-induced changes in systemic arterial pressure in stable dialysis patients. Hypertension 13: 213–218, 1989.CrossRefGoogle Scholar
  101. 101.
    Henrich WL, Hunt JM, Nixon JV: Increased ionized calcium and left ventricular contractility during hemodialysis. N Engl J Med 310: 19–23, 1984.PubMedCrossRefGoogle Scholar
  102. 102.
    Lang RB, Feltner SK, Neuman A, Bushinsky DA, Borow KM: Left ventricular contractility varies directly with blood ionized calcium. Ann Intern Med 108: 524–529, 1988.PubMedCrossRefGoogle Scholar
  103. 103.
    Morton AR, Hercz G, Coburn JW: Control of hyperphosphatemia in chronic renal failure. Semin Dial 3: 219–223, 1990.CrossRefGoogle Scholar
  104. 104.
    Mai ML, Emmett M, Shelkh MS, et al.: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36: 690–6695, 1989.PubMedCrossRefGoogle Scholar
  105. 105.
    Coburn JW: Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int 38 (Suppl 29):S54-S-61, 1990.Google Scholar
  106. 106.
    Slatopolsky E, Weerts C, Lopez-Hilker S: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315: 157–161, 1986.PubMedCrossRefGoogle Scholar
  107. 107.
    Slatopolsky E, Weerts C, Norwood K, et al.: Long-term effects of calcium carbonate and 2.5 mEq/L calcium dialysate on mineral metabolism. Kidney Int 36: 897–903, 1989.PubMedCrossRefGoogle Scholar
  108. 108.
    Sawyer N, Noonan K, Altmann P, Marsh F, Cunningham J: High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminum avoidance in hemodialysis patients. Nephrol Dial Transpl 4: 105–109, 1989.Google Scholar
  109. 109.
    Van der Merwe WM, Rodger RSC, Grant AC: Low calcium dialysate and high-dose oral calcetriol in the treatment of secondary hyperparathyroidism in haemodialysis patients. Nephrol Dial Transplant 5: 874–877, 1990.PubMedCrossRefGoogle Scholar
  110. 110.
    Ketchersid TL, Van Stone JC: Dialysate potassium. Semin Dial 4: 46–51, 1991.CrossRefGoogle Scholar
  111. 111.
    Spital A, Sterns RH: Potassium homeostasis in dialysis patients. Semin Dial 1:14–20, 1988.Google Scholar
  112. 112.
    Sherman RA, Hwang ER, Bernholz AS, Eisinger RP: Variability in potassium removal by hemodialysis. Am J Nephrol 6: 284–288, 1986.PubMedCrossRefGoogle Scholar
  113. 113.
    Feig PU, Shook A, Sterns RH: Effect of potassium removal during hemodialysis on the plasma potassium concentration. Nephron 27: 25–30, 1981.PubMedCrossRefGoogle Scholar
  114. 114.
    Hou S, McElroy PA, Nootens J, Beach M: Safety and efficacy of low-potassium dialysate. Am J Kidney Dis 13: 137–143, 1989.PubMedGoogle Scholar
  115. 115.
    Morgan AG, Burkinshaw L, Robinson PJA, Rosen SM: Potassium balance and acid-base changes in patients undergoing regular hemodialysis therapy. Br Med J L•779–783, 1970.Google Scholar
  116. 116.
    Morrison G, Michelson EL, Brown S, Morganroth J: Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients. Kidney Int 17: 811–819, 1980.PubMedCrossRefGoogle Scholar
  117. 117.
    Wiegand CF, Davin TD, Raij LF, Kjellstrand CM: Severe hypokalemia induced by hemodialysis. Arch Intern Med 141: 167–170, 1981.PubMedCrossRefGoogle Scholar
  118. 118.
    Tokars JI, Alter MJ, Favero MS, Moyer LA, Bland LA: National surveillance of hemodialysis-associated diseases in the United States, 1990. Trans ASAIO 39: 71–80, 1993.Google Scholar
  119. 119.
    Alter MJ, Favero MS, Moyer LA, Bland LA: National surveillance of dialysis-associated diseases in the United States, 1989. Trans ASAIO 37: 97–109, 1991.Google Scholar
  120. 120.
    Dunea G, Mahurkas SD, Mamdani B, Smith EC: Role of aluminum in dialysis dementia. Ann Intern Med 88: 502–504, 1978.PubMedCrossRefGoogle Scholar
  121. 121.
    Coburn JW, Norros KC, Sherrard DJ, Bia M, Dach F, Alfrey A, Slatopolsky E: Toxic effects of aluminum in end-stage renal disease: discussion of a case. Am J Kidney Dis 12: 17 1184, 1988.Google Scholar
  122. 122.
    Llach F, Felsenfeld AJ, Coleman MD, Keveney JJ Jr, Pederson JA, Medlock R: The natural course of dialysis osteomalacia. Kidney Int 29 (Suppl 18): S74 - S79, 1986.Google Scholar
  123. 123.
    Centers for Disease Control: Dialysis dementia from aluminum. Epidemic Investigation Report EPI 81–39–2, June 10, 1982. CDC, Atlanta, 1982.Google Scholar
  124. 124.
    Topple MA, Bland LA, Favero MS, Jarvis WR: Investigation of hemolytic anemia after chloramine exposure in a dialysis center (letter). Trans ASAIO 34: 1060, 1988.Google Scholar
  125. 125.
    Yawata Y, Kjillstrand C, Buselmeier T, Howe R, Jacob H: Hemolysis in dialyzed patients: tap water-induced red blood cell metabolic deficiency. Trans ASAIO 18: 301–304, 1992.CrossRefGoogle Scholar
  126. 126.
    Neilan BA, Ehlers SM, Kolpin CF, Eaton JW: Prevention of chloramine-induced hemolysis in dialyzed patients. Clin Nephrol 10: 105–108, 1978.PubMedGoogle Scholar
  127. 127.
    Gordon SM, Drachman J, Bland LA, Reid MH, Favero M, Jarvis WR: Epidemic hypotension in a dialysis center caused by sodium azide. Kidney Int 37: 110–115, 1990.PubMedCrossRefGoogle Scholar
  128. 128.
    Anderson R, Beard JH, Sorley D: Fluoride intoxication in a dialysis unit. Maryland MMWR 29: 134–136, 1980.Google Scholar
  129. 129.
    Lough J, Noonan R, Gagnon R, Kaye M: Effects of fluoride on bone in chronic renal failure. Arch Pathol 99: 484–487, 1975.PubMedGoogle Scholar
  130. 130.
    National News. Dialysis patients in Chicago die from fluoride poisoning; FDA issues safety alert. Contemp Dial Nephrol (Nov): 10–11, 1993.Google Scholar
  131. 131.
    Freeman RM, Lawton RL, Chamberlain MA: Hard-water syndrome. N Engl J Med 276: 1113–1118, 1967.PubMedCrossRefGoogle Scholar
  132. 133.
    Evans DB, Slapak M: Pancreatitis in the hard water syndrome. Br Med J 3: 748, 1975.PubMedCrossRefGoogle Scholar
  133. 133.
    Carlson DJ, Shapiro FL: Methemoglobinemia from well water nitrates: a complication of home dialysis. Ann Intern Med 73: 757–759, 1970.PubMedCrossRefGoogle Scholar
  134. 134.
    Manzler AD, Schreiner CW: Copper-induced acute hemolytic anemia. A new complication of hemodialysis. Ann Intern Med 73: 409–412, 1970.PubMedCrossRefGoogle Scholar
  135. 136.
    Matter BJ, Pederson J, Psimenos G, Lindeman RD: Lethal copper intoxication in hemodialysis. Trans ASAIO 15: 309315, 1969.Google Scholar
  136. 136.
    Gallery EDM, Blomfield J, Dixon SR: Acute zinc toxicity in haemodialysis. Br Med J 4: 33, 1973.CrossRefGoogle Scholar
  137. 137.
    Centers for Disease Control. Formaldehyde intoxication associated with hemodialysis–California. Epidemic Investigation Report EPI 81–73–2, May 7, 1984. CDC, Atlanta, 1984.Google Scholar
  138. 138.
    Orringer EP, Mattem WD: Formaldehyde-induced hemolysis during chronic hemodialysis. N Engl J Med 294: 1416 1420, 1976.Google Scholar
  139. 139.
    Nickey WA, Chinitz VL, Kim KE, Onesti G, Swartz C: Hypernatremia from water softener and malfunction during home dialysis. JAMA 214: 915–916, 1976.CrossRefGoogle Scholar
  140. 140.
    Vlchek DL: Staying tuned in to the high-tech world. Part 3: Water treatment update. Dial Transplant 19: 119–124, 1990.Google Scholar
  141. 141.
    Vlchek DL: Monitoring a hemodialysis water treatment system. In: AAMI Standards and Recommended Practices. Vol. 3: Dialysis. American National Standards, Arlington, VA, pp 267–277, 1993.Google Scholar
  142. 142.
    Johnson WJ, Taves DR: Exposure to excessive fluoride during hemodialysis. Kidney Int 5: 451–454, 1974.PubMedCrossRefGoogle Scholar
  143. 143.
    Association for the Advancement of Medical Instrumentation. In: AAMI Standards and Recommended Practices. Vol. 3: Dialysis. American National Standards, Arlington, VA, pp 1–332, 1993.Google Scholar
  144. 144.
    Favero MS, Petersen NJ, Carson LA, Bond WW, Hindman 418, 1986. SH: Gram negative water bacteria in hemodialysis systems. Health Lab Sci 12: 321–334, 1975.Google Scholar
  145. 145.
    Bland LA, Favero MS: Microbiologic aspects of hemodialysis systems. In: AAMI Standerds and Recommended Practices. Vol. 3: Dialysis. American National Standards, Arlington, VA, pp 257–265, 1993.Google Scholar
  146. 146.
    Carson LA, Bland LA, Cusick LB, Favero MS, Bolan GA, Reingold AL, Good RC: Prevalence of non-tuberculous my- cobacterial in water supplies of hemodialysis centers. Appl Environ Microbiol 54 (12): 3122–3125, 1988.PubMedGoogle Scholar
  147. 147.
    Lowry P, Beck-Sague CM, Bland LE, Aguero SM, Ardiuno 175, 1988. MJ, Minuth AN, Murray RA, Swenson JM, Jarvis WR: My- cobacterium Chelones infections among patients receiving high-flux dialysis in a hemodialysis unit in California. J Infect Dis 161: 85–90, 1990.Google Scholar
  148. 148.
    Bolan G, Reingold AL, Carson LA, Silcox VA, Woodley CL, NJ, Favero MS, Good RC, Browne CV: Infestious with Mycobactrium Chelonei in patients receiving dialysis and us- ing processed hemodialyzers. J Infect Dis 152:1013–1019, Hayes PS, Hightower AW, McFarland L, Brown J, Peterson 1985.Google Scholar
  149. 149.
    Carson La, Petersen NJ, Favero MS, Aguero SM: Growth characteristics of Atypi cal mycobacteria in water and their comparative resistance to disinfectants. Appl Environ Microbiol 36: 839–846, 1978.Google Scholar
  150. 150.
    Favero MS: Distinguishing between high-level disinfection, reprocessing, and sterilization. IN: AAMI, Reuse of Disposables: Implications for Quality Health Care and Cost Containment. Technical Assessment Report No. 6, Arling-ton, VA, pp 19–20, 1983.Google Scholar
  151. 151.
    Favero MS, Bland LA: Microbiologic principles applied to reprocessing hemodialyzers. In: N Deane, RJ Wineman, JA Bemis, eds, Guide to Reprocessing of Hemodialyzers. Martinus Nijhoff, Boston, pp 63–73, 1986.CrossRefGoogle Scholar
  152. 152.
    Gordon SM, Oettinger CW, Bland LA, Oliver JC, Arduino MJ, Aguero SM, McAllister SK, Favero MS, Jarvis WR: Pyrogenic reactions in patients receiving conventional, high-efficiency, or high-flux hemodialysis treatments with bicar bonate dialysate containing high concentrations of bacteria and endotoxin. J Am Soc Nephrol 2: 1436–1444, 1992.PubMedGoogle Scholar
  153. 153.
    Favero MS, Petersen NJ, Boyer KM, Carson LA, Bond WW: Microbial contamination of renal dialysis systems and associ-ated health risks. Trans ASAIO 20: 175–183, 1974.Google Scholar
  154. 154.
    Klein E, Pass T, Harding GB, Wright R, Millon C: Microbial and endotoxin contamination in water and dialysate in the central United States. Artif Organs 14: 85–94, 1990.PubMedCrossRefGoogle Scholar
  155. 155.
    Bland LA, Ridgeway MR, Aguero SM, Carson LA, Favero MS: Potential bacteriologic and endotoxin hazards associ-ated with liquid bicarbonate concentrate. Trans ASAIO 33: 542–545, 1987.Google Scholar
  156. 156.
    Pegues DA, Oettinger CW, Bland LA, Oliver JC, Arduino MJ, Aguero SM, McAllister SK, Gordon SM, Favero MS, Jarvis WR: A prospective study of pyrogenic reactions in hemodialysis patients using bicarbonate dialysis fluids filtered to remove bacteria and endotoxin. J Am Soc Nephrol 2: 1002–1007, 1992.Google Scholar
  157. 157.
    Centers for Disease Control: Clusters of bacteremia and pyrogenic reactions in hemodialysis patients—Georgia. Epidemic Investigation Report EPI86–65–2, April 22, 1987.Google Scholar
  158. 158.
    Centers for Disease Control: Bacteremia associated with reuse of disposble hollow-fiber hemodialyzers. MMWR 35: 417Google Scholar
  159. 159.
    Centers for Disease Control: Pyrogenic reactions in patients undergoing high–flux hemodialysis—California. Epidemic In vestigation Report EPI 86–80–2, June 1, 1987. CDC, Atlanta,1987.Google Scholar
  160. 160.
    Alter MJ, Favero MS, Miller JK, Coleman Pi, Bland LA: Reuse of hemodialyzers. Results of nationwide surveillance for adverse effects. JAMA 260: 2073–2076, 1988.PubMedCrossRefGoogle Scholar
  161. 161.
    Bland LA, Favero MS, Oxborrow GS, Agnero SM, Seavy BP, Danielson JW: Effect of chemical germicides on the integrity of hemodialyzer membranes. Trans ASAIO 34: 172–175, 1988.Google Scholar
  162. 162.
    Jenkins SR, Lin FUC, Lin RS, Israel I, Petersen NJ: Pyro genic reactions and pseudomonas bacteremias in a hemo dialysis center. Dial Transplant 16: 192–197, 1987.Google Scholar
  163. 163.
    Oberle MW, Favero MS, Carson LA, Medina MS, Ramirez Puente M, Perez-Figueroa S: Fatal endotoxemia in dialysis patients at a summer camp. Dial Transplant 9: 549–550, 1980.Google Scholar
  164. 164.
    Bolan G, Reingold AL, Carson LA, Silcox VA, Woodley CL, Hayes PS, Hightower AW, McFarland L, Brown J, Petersen NJ, Favero MS, Good RC, Browne CV: Infections with Mycobactreium chelonia in patients receiving dialysis and using processed hemodialyzers. J Infect Dis 152: 1013–1019, 1985.PubMedCrossRefGoogle Scholar
  165. 165.
    Bland LA, Favero MS: Microbiologic and endotoxin consid erations in hemodialyzer reprocessing. In: AAMI Standards and Recommended Practices. Vol. 3: Dialysis. American Na tional Standards, Arlington, VA, pp 45–52, 1993.Google Scholar
  166. 166.
    Gazenfield-Grazit E, Eliabou HE: Endotoxin antibodies in patients on maintenance hemodialysis. Israel J Med Sci 5: 1032–1035, 1969.Google Scholar
  167. 167.
    Jones DM, Tobin BM, Harlow GR, Ralston Ai: Antibody production in patients on regular hemodialysis to organisms present in dialysate. Proc Eur Dial Transplant Assoc 9: 575–576, 1972.PubMedGoogle Scholar
  168. 168.
    Hindman SH, Favero MS, Carson LA, Petersen NJ, Schonberger LB, Solanto JT: Pyrogenic reactions during haemodialysis caused by entramural endotoxin. Lancet 2: 732–734, 1975.PubMedCrossRefGoogle Scholar
  169. 169.
    Raij L, Shapiro FL, Michael AF: Endotoxemia in febrile reactions during hemodialysis. Kidney Int 4: 57–60, 1973.PubMedCrossRefGoogle Scholar
  170. 170.
    Passavanti G, Buongiorno E, De Fino G, Fumarola D, Coratelli P: The permeability of dialytic membranes to en dotoxins: clinical and experimental findings. Int J Artif Or gans 12: 505–508, 1989.Google Scholar
  171. 171.
    Dinarello CA: Interleukin-1 and its biologically related cytokines. Adv Immunol 44: 153–205, 1989.PubMedCrossRefGoogle Scholar
  172. 172.
    Loppnon H, Brade H, Durbaum I, Dinarello CA, Kusumoto S, Rictschel ET, Flad HO: IL-1 induction-capacity of defined lipopolysaccharide partial structures. J Immunol 142: 3229–3238, 1989.Google Scholar
  173. 173.
    Duff GW, Atkins E: The detection of endotoxin by in-vitro production of endogenous pyrogen: comparison with limulus amebocyte lysate gelation. J Immunol Methods 52: 323–331, 1982.PubMedCrossRefGoogle Scholar
  174. 174.
    Lonnemann G, Bingel M, Floege J, Koch KM, Shaldon S, Dinarello CA: Detection of endotoxin-like interleukin-1 inducing activity during in vitro dialysis. Kidney Int 33: 29–35, 1988.PubMedCrossRefGoogle Scholar
  175. 175.
    Lonnemann G: Dialysate bacteriological quality and the per meability of dialyzer membranes to pyrogenes. Kidney Int 43 (Suppl 41): S195–S200, 1993.Google Scholar
  176. 176.
    Favero MS, Port FK, Bernick JJ: In vivo studies of dialysis related endotoxemia and bacteremia. Nephron 27: 307–312, 1981.PubMedCrossRefGoogle Scholar
  177. 177.
    Klinkman H, Falkenhagen D, Smollich BP: Investigation of permeability of highly permeable polysulfone membranes for pyrogens. Contrib Nephrol 46: 174–183, 1985.Google Scholar
  178. 178.
    Bingel M, Lonnemann G, Sheldon S, Koch KM, Dinarello CA: Human interleukin-1 production during hemodialysis. Nephron 43: 161–163, 1986.PubMedCrossRefGoogle Scholar
  179. 179.
    Lonnemann G, Endress S, Van Der Meer JWM, Cannon JG, Koch KM, Dinarello CA: Differences in the synthesis and kinetics of release of interleukin-la, interleukin-113, and tumor necrosis factor from human mononuclear cells. Eur J Immunol 19: 1531–1536, 1987.CrossRefGoogle Scholar
  180. 180.
    Hakim RM, Breillat J, Lazarus JM, Port FK: Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med 311: 878–882, 1984.PubMedCrossRefGoogle Scholar
  181. 181.
    Cavallon J-M, Fitting C, Haeffner-Cavaillon N: Recombinant C5a enhances interleukin-1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol 20: 253–257, 1990.CrossRefGoogle Scholar
  182. 182.
    Schindler R, Gelfand JA, Dinarello CA: Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself. Blood 76: 1631–1638, 1990.PubMedGoogle Scholar
  183. 183.
    Urena P, Herbelin A, Zingraff J, Lair M, Man NK, Descamps-Latscha B, Drucke T: Permeability of cellulosic and non-cellulosic membranes to endotoxins subunits and cytokine production during in-vitro haemodialysis. Nephrol Dial Transplant 7: 16–28, 1992.PubMedGoogle Scholar
  184. 184.
    Heberlin A, Urena P, Man NK, Drueke T, Descamp-Latscha B: In vitro studies of endotoxin transfer across cellulosic and non-cellulosic dialysis membranes. Part II. Interleukin-1 production. Contrib Nephrol 74: 79–85, 1989.Google Scholar
  185. 185.
    Dinarello CA, Koch KM, Shaldon S: Interleukin 1 and its relevance to patients treated with hemodialysis. Kidney Int 33 (Suppl 24): S21 - S26, 1988.Google Scholar
  186. 186.
    Bingel M, Lonnemann G, Shaldon S, Koch KM, Dinarello CA: Human interleukin-1 production during hemodialysis. Nephron 43: 161–163, 1986.PubMedCrossRefGoogle Scholar
  187. 187.
    Haeffner-Cavaillon N, Cavaillon JM, Ciancioni C, Bade F, Delons S, Kazatchkine MD: In vivo induction of interleukin1 during hemodialysis. Kidney Int 35: 1212–1218, 1989.PubMedCrossRefGoogle Scholar
  188. 188.
    Schindler R, Lonnemann G, Shaldon S, Koch KM, Dinarello CA: Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement. Kidney Int 37: 85–93, 1990.PubMedCrossRefGoogle Scholar
  189. 189.
    Pearson FC, Bohan JLW, Bruner G: Comparison of chemical analysis of hollow-fiber dialyzer extracts. J Artif Organs 8: 291–298, 1984.CrossRefGoogle Scholar
  190. 190.
    Harding GB, Pass T, Million C, Wright R, DeJarnette J, Klein E: Bacterial contamination of haemodialysis center water and dialysate: are current assays adequate? Artif Organs 13: 155–169, 1989.PubMedCrossRefGoogle Scholar
  191. 191.
    Gould MJ: Performing the LAL gel-clot test in facilities. Nephrol News Issues 2911: 26–29, 1988.Google Scholar
  192. 192.
    Hakim RM, Friedrich RA, Lowrie EG: Formaldehyde kinetics in reused dialyzers. Kidney Int 28: 936–943, 1985.PubMedCrossRefGoogle Scholar
  193. 193.
    Kaufman AM, Frinak S, Godmere RO, Levin NW: Clinical experience with heat sterilization for reprocessing dialyzers. ASAIO J 38: M338 - M340, 1992.PubMedCrossRefGoogle Scholar
  194. 194.
    Vanholder R, NoensL, Eng RDS, Ringoior S: Development of anti-N-like antibodies during formaldehyde reuse in spite of adequate predialysis rinsing. Am J Kidney Dis 11: 477–480, 1988.Google Scholar
  195. 195.
    Pegues DA, Beck-Sague CM, Woollen SW, Reeenspan B, Burns SM, Bland LA, Ardeuno MJ, Favero MS, Mackow RC, Jarvis WR: Anaphylactoid reactions associated with reuse of hollow-fiber hemodialyzer and ACE inhibitor. Kidney Int 42: 1232–1237, 1992.PubMedCrossRefGoogle Scholar
  196. 196.
    Schmitter L, Sweet S: Anaphylactic reactions with the addition of hypochlorite to reuse in patients maintained on reprocessed polysulfone hemodialyzers and ACE inhibitors. Paper presented at the annual meetings of the American Society of Artificial Internal Organs, New Orleans, April 1993.Google Scholar
  197. 197.
    U.S. Department of Health and Human Services, Food and Drug Administration: Tlk Paper T92–46, October 13, 1992.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Nuhad Ismail
    • 1
  • Bryan Becker
    • 1
  • Raymond M. Hakim
    • 1
  1. 1.Division of NephrologyVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations